
NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity

Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.

This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments

Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.

Patient-relevant outcomes sit at the heart of the EU HTA reforms, but ensuring they reflect lived experience requires you to look beyond what traditional clinical endpoints measure.

MS affects nearly three million people worldwide and has three main types

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

True "beyond-the-pill" strategy requires shifting from a prescriptive model to a supportive one—using personalized digital tools and authentic patient voices to drive adherence, improve outcomes, and prove value.

Litfulo delivered significant, clinically meaningful improvements for both face and body